Vancomycin Can Be Given in Pregnancy
Yes, vancomycin can be safely administered during pregnancy when clinically indicated for serious bacterial infections. 1, 2
Safety Profile by Trimester
First Trimester (T1)
- Probably safe classification 1
- Experience during T1 is limited, but available data show no evidence of teratogenicity 2
- Animal reproduction studies have not been conducted, but no mutagenic potential has been found 2
Second and Third Trimesters (T2/T3)
- Compatible classification 1
- A controlled clinical study evaluated vancomycin in pregnant women with serious staphylococcal infections during T2 and T3 2
- No sensorineural hearing loss or nephrotoxicity attributable to vancomycin was noted in infants 2, 3
- One infant whose mother received vancomycin in T3 experienced conductive hearing loss that was NOT attributed to vancomycin and spontaneously resolved 2, 3
Key Clinical Evidence
The FDA label explicitly states that vancomycin crosses the placenta - it is found in cord blood 2. However, multiple studies demonstrate safety:
- A prospective study of 10 pregnant women treated with IV vancomycin for methicillin-resistant Staphylococcus aureus infections showed normal auditory brainstem responses and renal function in all infants 3
- Vancomycin pharmacokinetics in pregnant women are consistent with non-pregnant adults, with similar AUC₀₋₂₄ values (223 vs 226 μg·h/mL) 4
- Most neonates (92.3%) achieve therapeutic cord blood levels above the MIC breakpoint for Group B Streptococcus after maternal intrapartum vancomycin 5
Specific Clinical Scenarios
Group B Streptococcus Prophylaxis
Vancomycin is recommended for penicillin-allergic women at high risk for anaphylaxis when clindamycin/erythromycin are not options due to resistance 6. The 2002 CDC guidelines support this use, though they note concerns about vancomycin resistance emergence 6.
Cesarean Section Prophylaxis
For women colonized with methicillin-resistant Staphylococcus aureus (MRSA), vancomycin 1.5 mg/kg IV (infused over ≥60 minutes) is recommended 7. However, it is reserved specifically for MRSA carriers and not used routinely 7.
Serious Infections
For life-threatening infections requiring vancomycin, the direct maternal benefit outweighs potential fetal risk 1. The principle is clear: untreated serious maternal infection poses greater risk to both mother and fetus than vancomycin exposure 1.
Dosing Considerations
- Standard adult dosing regimens (15-20 mg/kg every 8-12 hours) are appropriate 8, 9
- Vancomycin clearance increases with pregnancy due to increased renal clearance and volume of distribution 4, 9
- Therapeutic drug monitoring is mandatory for prolonged therapy 9
- Target AUC₂₄ of 400-600 mg·h/L is appropriate, similar to non-pregnant patients 4
Breastfeeding
Vancomycin is present in breast milk in nonsignificant amounts with low oral bioavailability 1. The FDA label states caution should be exercised, but the risk to the nursing infant is minimal due to poor oral absorption 2.
Critical Caveats
- The FDA label states vancomycin should only be given to pregnant women "if clearly needed" 2 - this means when treating serious infections where benefits outweigh risks
- Vancomycin use should be reserved for appropriate indications to minimize development of drug-resistant bacteria 2
- Monitor renal function when using vancomycin with other potentially nephrotoxic drugs 2
- Infusion-related reactions (hypotension, flushing, "red man syndrome") can occur - infuse over ≥60 minutes 2
Bottom line: Vancomycin is probably safe in T1 and compatible in T2/T3 when treating serious gram-positive infections. Use standard adult dosing with therapeutic drug monitoring, and reserve for appropriate clinical indications where safer alternatives are inadequate.